StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
AGM/EGMNov 12, 2026, 06:06 AM

Mesoblast Limited Announces All Resolutions Passed at AGM

AI Summary

Mesoblast Limited held its Annual General Meeting on November 10, 2026, where all proposed resolutions were passed by shareholders. Key approvals included the adoption of the Remuneration Report, the re-election of Mr. Philip Facchina, and the election of Mr. Jon Voigtman as a Director. Additionally, shareholders approved the issuance of stock options and restricted stock units to key executives, including Dr. Silviu Itescu and Dr. Eric Rose, as well as other individuals, and the Mesoblast Limited Restricted Stock Unit Plan.

Key Highlights

  • Mesoblast Limited announced all resolutions passed at the Annual General Meeting held on November 10, 2026.
  • Approval granted for the adoption of the Remuneration Report with 71.81% of votes in favor.
  • Re-election of Mr. Philip Facchina as a Director approved with 92.82% of votes in favor.
  • Election of Mr. Jon Voigtman as a Director approved with 81.08% of votes in favor.
  • Approval granted for the proposed issue of options to Dr. Silviu Itescu for long-term and short-term incentives.
  • Approval granted for the proposed issue of options to Chief Medical Officer, Dr. Eric Rose.
  • Approval granted for the Mesoblast Limited Restricted Stock Unit Plan.
  • Approval granted for the proposed issue of Restricted Stock Units to various individuals including Mr. Philip Facchina and Ms. Lyn Cobley AM.